Loading
Giving immunotherapy for a few weeks before surgery produces a tumour sample that shows exactly what the drug did. That is the fastest way to learn who responds.
Neoadjuvant window trials deliver paired baseline and post-treatment tissue plus a pathological response readout within weeks, and they have already produced high-quality mechanistic insight in melanoma, colorectal cancer with mismatch repair deficiency and bladder cancer. Standardising a shared window protocol across tumour types, with common tissue handling and open data release, would turn scattered studies into a systematic discovery platform.
Shares Major pathological response (MPR), NADINA, Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
Shares Christian Blank, NADINA, Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, RNA sequencing & expression profiling, Bladder & urothelial cancer.
Shares Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work, Single-cell & spatial profiling, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Neoadjuvant / adjuvant / perioperative.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Trial design, endpoints and cost, Bladder & urothelial cancer.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, No one can predict who responds to immunotherapy, Colorectal cancer.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Failures are hidden, RNA sequencing & expression profiling.
Shares Major pathological response (MPR), NADINA, Melanoma, Immune checkpoint inhibitors.